The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for game-changing treatments and substantial returns is undeniable, the connected risks are also considerable. Many